Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines. 1994

L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
Institute for Surgical Research, Rikshospitalet Oslo, Norway.

Plasminogen activators (PAs) and their inhibitors (PAIs) can be produced by tumor cells and surrounding inflammatory cells and fibroblasts. The present study evaluate both the expression and release of PAs (uPA and tPA) and PAIs (PAI-1 and PAI-2) from cultured cells, and also the expression of uPA receptor (uPAR). Immunocytochemistry showed that PAs, PAIs and uPAR were present to different extents on the surface of colon carcinoma cells (Caco-2, HT-29), malignant melanoma cells (LOX) and normal fibroblasts. uPA immunoreactivity was intermediate in Caco-2, HT-29 and LOX and weak in the fibroblasts. tPA immunoreactivity was intermediate in Caco-2 and LOX and weak in HT-29 and fibroblasts. PAI-1 and PAI-2 immunoreactivities were absent in HT-29, weak in Caco-2 and strong in fibroblasts. In LOX the immunoreactivity was intermediate for PAI-1 and strong for PAI-2. uPAR immunoreactivity was weak in Caco-2, HT-29 and LOX and negative in fibroblasts. ELISAs on conditioned medium detected that the colon carcinoma cells Caco-2 and HT-29 did not release any PAs or PAIs. LOX released tPA (median 9 ng/million cells at 72 hours), PAI-1 (1050 ng/million cells) and PAI-2 (245 ng/million cells), and fibroblasts released uPA (1 ng/million cells) and PAI-1 (910 ng/million cells). These results show that both tumor cells and fibroblasts express tissue destructive enzymes, PAs and PAIs, whereas only the tumor cells express the uPAR required for focalization and regulation of PA activity at the cell surface. The melanoma cells LOX and fibroblasts also released PAs and PAIs, in contrast to the colon carcinoma cells Caco-2 and HT-29.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
November 1986, International journal of cancer,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
August 1990, Cancer research,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
June 2000, International journal of cancer,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
March 1990, Cancer research,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
January 1988, Methods in enzymology,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
November 1993, The American journal of gastroenterology,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
February 1993, American journal of hematology,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
January 1994, The American journal of pathology,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
July 1986, The Journal of biological chemistry,
L Buø, and K Bjørnland, and T S Karlsrud, and D Kvale, and I Kjønniksen, and O Fodstad, and P Brandtzaeg, and H T Johansen, and A O Aasen
June 1985, British journal of cancer,
Copied contents to your clipboard!